News
BIOC
0.5310
-3.45%
-0.0190
BRIEF-Biocept Inc Estimates It Will Incur Charges Of About $0.6 Mln For Q1 2023 Severance Costs
Reuters · 01/06 12:23
Biocept explores strategic alternatives, to cut workforce by 35%
Seeking Alpha · 01/06 12:17
Biocept To Explore Strategic Alternatives And Implement Restructuring Plan
Benzinga · 01/06 11:55
Biocept to Cut 35% of Workforce in Restructuring Plan, Explore Strategic Alternatives
Biocept to Cut 35% of Workforce in Restructuring Plan, Explore Strategic Alternatives
MT Newswires · 01/06 07:43
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 12/12/2022 13:06
Biocept Q3 EPS $(0.33) Down From $(0.04) YoY, Sales $5.59M Down From $17.47M YoY
Benzinga · 11/21/2022 21:10
BRIEF-Biocept Reports Third Quarter 2022 Financial Results
Reuters · 11/21/2022 21:08
Biocept Q3 Loss Widens, Revenue Drops
Biocept Q3 Loss Widens, Revenue Drops
MT Newswires · 11/21/2022 16:57
-- Earnings Flash (BIOC) BIOCEPT Posts Q3 Revenue $5.6M
-- Earnings Flash (BIOC) BIOCEPT Posts Q3 Revenue $5.6M
MT Newswires · 11/21/2022 16:11
BRIEF-Biocept Appoints Financial Executive Quyen Dao-Haddock To Its Board Of Directors
Reuters · 11/18/2022 13:06
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors
SAN DIEGO, November 18, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately, increasing Board membersh...
Business Wire · 11/18/2022 13:00
Biocept Announces Participation In An Investigator-Initiated Study To Better Understand The Development And Progression Of Metastatic Breast Cancer To The Central Nervous System
Benzinga · 11/16/2022 13:10
Biocept GAAP EPS of -$0.31, revenue of $10.6M
Seekingalpha · 11/10/2022 22:01
Biocept Q3 EPS $(0.31) Down From $(0.14) YoY, Sales $10.61M Down From $12.05M YoY
Benzinga · 11/10/2022 21:58
BRIEF-Biocept Reports Second Quarter 2022 Financial Results
Reuters · 11/10/2022 21:28
-- Earnings Flash (BIOC) BIOCEPT Reports Q2 Revenue $10.6M
-- Earnings Flash (BIOC) BIOCEPT Reports Q2 Revenue $10.6M
MT Newswires · 11/10/2022 16:28
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers ASLAN Pharma (NASDAQ:ASLN) stock moved upwards by 13.7% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $37.6 million.
Benzinga · 10/19/2022 22:23
Biocept to Present at the LD Micro Main Event XV
SAN DIEGO, October 19, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that management will present at the LD Micro Main Event XV on Wednesday, October 26 at 2:30 p.m. Pacific time (5:...
Business Wire · 10/19/2022 12:00
Biocept Expands Commercial Offering Of CNSide Assay To Most Cancers That Metastasize To The Central Nervous System
Biocept, Inc. (NASDAQ:BIOC), a leading provider of molecular diagnostic assays, products, and services, announces the expanded commercial availability of CNSide for patients with metastatic melanoma.
Benzinga · 10/17/2022 12:05
Biocept to Host KOL Webinar Today to Discuss its Proprietary CNSide™ Assay to Detect and Quantify Cancer that Metastasized to the Central Nervous System
SAN DIEGO, October 14, 2022--Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces an hour-long webinar to be held today, October 14 at 1 p.m. Eastern time featuring case studies presented by lead...
Business Wire · 10/14/2022 12:00
More
Webull provides a variety of real-time BIOC stock news. You can receive the latest news about Biocept Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIOC
Biocept, Inc. is a molecular oncology diagnostics company. The Company focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood, and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name of CNSide. In addition to CNSide, its current blood-based testing includes its Target Selector technologies, which enables detection of specific gene mutations, such as EGFR, KRAS or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells (CTCs) isolated from blood. Its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach provides both high-sensitivity and specificity and is applicable to a range of diagnostic applications in patients with metastatic carcinoma. It provides blood-based liquid biopsy technology.